Arbutus (ABUS) delivered earnings and revenue surprises of -8.70% and -17.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 6天前
Recap: Arbutus Biopharma Q2 Earnings
Shares of Arbutus Biopharma (NASDAQ:ABUS) fell 1% in pre-market trading after the company reported Q2 results.Quarterly Results Earnings per share rose 45.65% over the past year to ($0.25), which missed the estimate of ($0.24).Revenue of $1,514,000 up by 116.2
Benzinga · 6天前
Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Phase 1a/1b clinical trial for AB-729, a subcutaneously delivered RNAi agent, remains on track with results from additional cohorts expected in the second half of 2020 AB-836, an oral capsid inhibitor, remains on track for completion of IND enabling studies b
GlobeNewswire · 6天前
Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference
WARMINSTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with chronic hepatitis B virus (HBV) infection, as well as therapies t
GlobeNewswire · 08/05 12:00
Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know
Arbutus (ABUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.